None; None

Resúmenes

Los antiinflamatorios no esteroideos comprenden un grupo heterogéneo químicamente de sustancias que comparten acciones terapéuticas. Entre ellos la aspirina o ácido acetil salicílico. Este es el agente analgésico antiplaquetario y antipirético de mayor consumo y el patrón de referencia para valorar los demás fármacos. A su vez, es el antiagregante plaquetario más utilizado en el mundo. Sin embargo se habla hoy en día sobre el término de resistencia a la aspirina, su diagnóstico y su relevancia clínica como un factor importante de la eventual falla terapéutica de este medicamento.

Resistencia a la aspirina; agregación plaquetaria; falla terapéutica

Non steroideal anti-inflammatory drugs consist of a chemically heterogeneous group of substances that share the same therapeutic actions. Including aspirin or acetylsalicylic acid. This is the antiplatelet agent analgesic and antipyretic of higher consumption and represents the refference pattern for testing other drugs. In addition , it is the most widely used antiplatelet agent in the world . The term aspirin resistance is frequently used, it entails a diagnosis and has a clinical relevance being an important issue for the eventual therapeutic failure of this drug.

Aspirin resistance; platelet aggregation; therapeutic failure

Olman ^*+

Key

figura:

figura

Bibliografía

Referencias bibliográficas

1. Hankey, G. J & Eikelboom, J. W. (2006, 18 Feb) Aspirin resistance. Lancet, 367, 9510, 606- 17.
2. Weitz, J. I. (2011). Chapter 30. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. In: L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds), Goodman & Gilmans The Pharmacological Basis of Therapeutics, 12e.
3. Macchi, L., Sorel, N., et al. (2006). Aspirin Resistance: Definitions, Mechanisms, Prevalence, and Clinical Significance. Current Pharmaceutical Design, 12, 251-258.
4. Divani, A. A. (2013). Antiplatelet Therapy: Aspirin Resistance and All That Jazz! Clinical and Applied Thrombosis. Hemostasis, 19, 1, 5-18.
5. Gaglia, M. A. (2013). Cardiovascular Pharmacology Core Reviews: Aspirin. Journal of Cardiovascular Pharmacology and Therapeutics, 18, 6, 505-513.
6. Yerges, L. M. (2013). Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed Pharmacogenomics. Clinical pharmacology & Therapeutics, 94, 4.
7. Floyd, Ch. N. (2013). The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a sytematic review and meta-analysis. Br J Clin Pharmacol, 77, 3, 446457.
8. Weitz, J. I. (2012). Chapter 118. Antiplatelet, Anticoagulant, and Fibrinolytic Drugs. In Longo D. L., Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J., Loscalzo, J. (Eds), Harrisons Principles of Internal Medicine, 18e.
9. Zehnder, J. L. (2012). Chapter 34. Drugs Used in Disorders of Coagulation. In Katzung, B. G., Masters, S. B., Trevor, A. J. (Eds), Basic & Clinical Pharmacology, 12e
10. Angiolillo, D. J., Giugliano, G. R. & Simon, D.I. (2011). Chapter 61. Pharmacologic Therapy for Acute Coronary Syndromes. In Fuster, V., Walsh, R. A., Harrington, R.. A. (Eds), Hursts The Heart, 13e.

^* Medicos generales egresados de la Universidad de Costa Rica. Correo electrónico: enrique1arce@gmail.com

Recibido para publicación el 7 de enero de 2015 Aceptado el 27 de enero de 2015

Fechas de Publicación

Publicación en esta colección
29 Mayo 2015
Fecha del número
Mar 2015

Histórico

Recibido
07 Ene 2015
Acepto
27 Ene 2015

[1] 1. Hankey, G. J & Eikelboom, J. W. (2006, 18 Feb) Aspirin resistance. Lancet, 367, 9510, 606- 17.

[2] 2. Weitz, J. I. (2011). Chapter 30. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. In: L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds), Goodman & Gilmans The Pharmacological Basis of Therapeutics, 12e.

[3] 3. Macchi, L., Sorel, N., et al. (2006). Aspirin Resistance: Definitions, Mechanisms, Prevalence, and Clinical Significance. Current Pharmaceutical Design, 12, 251-258.

[4] 4. Divani, A. A. (2013). Antiplatelet Therapy: Aspirin Resistance and All That Jazz! Clinical and Applied Thrombosis. Hemostasis, 19, 1, 5-18.

[5] 5. Gaglia, M. A. (2013). Cardiovascular Pharmacology Core Reviews: Aspirin. Journal of Cardiovascular Pharmacology and Therapeutics, 18, 6, 505-513.

[6] 6. Yerges, L. M. (2013). Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed Pharmacogenomics. Clinical pharmacology & Therapeutics, 94, 4.

[7] 7. Floyd, Ch. N. (2013). The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a sytematic review and meta-analysis. Br J Clin Pharmacol, 77, 3, 446457.

[8] 8. Weitz, J. I. (2012). Chapter 118. Antiplatelet, Anticoagulant, and Fibrinolytic Drugs. In Longo D. L., Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J., Loscalzo, J. (Eds), Harrisons Principles of Internal Medicine, 18e.

[9] 9. Zehnder, J. L. (2012). Chapter 34. Drugs Used in Disorders of Coagulation. In Katzung, B. G., Masters, S. B., Trevor, A. J. (Eds), Basic & Clinical Pharmacology, 12e

[10] 10. Angiolillo, D. J., Giugliano, G. R. & Simon, D.I. (2011). Chapter 61. Pharmacologic Therapy for Acute Coronary Syndromes. In Fuster, V., Walsh, R. A., Harrington, R.. A. (Eds), Hursts The Heart, 13e.

<span name="style_bold">Resistencia</span><span name="style_bold"> a la aspirina</span>

Resúmenes

Referencias bibliográficas

Fechas de Publicación

Histórico